Paper Details

  1. Home
  2. Paper Details

Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies.

Author: GasperiniClaudio, HaggiagShalom, ProsperiniLuca, RuggieriSerena, TortorellaCarla

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Dimethyl fumarate (DMF) is slightly more effective than teriflunomide (TRF) in reducing the short-term relapse risk (RR = 0.92, p = 0.01) in patients with relapsing-remitting multiple sclerosis. However, this difference tends to fade in studies including younger patients and a higher proportion of treatment-naïve subjects. There is no difference between DMF and TRF on the short-term risk of confirmed disability worsening (RR = 0.99, p = 0.69). While the risk of treatment discontinuation is similar across the two drugs, DMF is associated with a slightly higher risk of discontinuation due to side effects and adverse events.
Paper Details　
Original Abstract of the Article :
In the absence of head-to-head comparison trials, we aimed to compare the effectiveness of two largely prescribed oral platform disease-modifying treatments for relapsing-remitting multiple sclerosis, namely, dimethyl fumarate (DMF) and teriflunomide (TRF). We searched scientific databases to identi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480378/

データ提供：米国国立医学図書館（NLM）

Dimethyl Fumarate vs. Teriflunomide: A Head-to-Head Comparison for Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS), a chronic neurological disease that disrupts the flow of information within the brain and spinal cord, presents a significant challenge for patients and healthcare professionals. This meta-analysis aims to compare the effectiveness of two widely prescribed oral disease-modifying treatments for relapsing-remitting MS: dimethyl fumarate (DMF) and teriflunomide (TRF). The researchers analyzed data from real-world studies reporting a direct comparison of these two treatments, examining their impact on relapse rates, confirmed disability worsening (CDW), and treatment discontinuation. The findings suggest that DMF might be slightly more effective than TRF in reducing the short-term risk of relapse, particularly in younger and treatment-naive patients. However, TRF appears to be associated with a lower risk of treatment discontinuation due to side effects and adverse events.

DMF and TRF: A Balancing Act for MS Management

This meta-analysis provides valuable insights into the comparative effectiveness of DMF and TRF for managing relapsing-remitting MS. While DMF might offer a slight advantage in reducing relapse risk, TRF appears to be associated with a lower risk of treatment discontinuation due to side effects.

Navigating the Desert of MS Treatment

Managing MS is a journey through a complex and often unpredictable landscape, much like navigating a vast desert. This meta-analysis provides valuable insights for navigating this terrain, offering guidance on the potential benefits and risks associated with DMF and TRF. Remember, every step we take in this journey requires a careful assessment of the available options and a commitment to finding the best path forward.

Dr.Camel's Conclusion

This meta-analysis provides valuable insights into the comparative effectiveness of DMF and TRF for managing relapsing-remitting MS. While DMF might offer a slight advantage in reducing relapse risk, TRF appears to be associated with a lower risk of treatment discontinuation due to side effects. The findings highlight the importance of carefully considering the individual patient's needs and preferences when choosing a treatment option. Just as a camel adapts its strategy based on the changing desert landscape, we must remain adaptable and informed in our approach to MS management.

Date :
  1. Date Completed 2023-09-07
  2. Date Revised 2023-09-24
Further Info :

Pubmed ID

37528262

DOI: Digital Object Identifier

PMC10480378

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.